关于《来自美国食品药品监督管理局不良事件报告系统（FAERS）的替扎尼定与CYP1A2抑制剂药物相互作用的不成比例性分析》的评论 - Suppr

Suppr

超能文献

Comment on: "A Disproportionality Analysis of Drug-Drug Interactions of Tizanidine and CYP1A2 Inhibitors from the FDA Adverse Event Reporting System (FAERS)".

作者信息

Noguchi Yoshihiro

机构信息

Laboratory of Clinical Pharmacy, Gifu Pharmaceutical University, 1-25-4, Daigakunishi, Gifu-shi, 501-1196, Japan.

出版信息

Drug Saf. 2022 Dec;45(12):1551-1552. doi: 10.1007/s40264-022-01240-w. Epub 2022 Oct 12.

DOI:10.1007/s40264-022-01240-w

PMID:36223038

Abstract

摘要

相似文献

Comment on: "A Disproportionality Analysis of Drug-Drug Interactions of Tizanidine and CYP1A2 Inhibitors from the FDA Adverse Event Reporting System (FAERS)".

Drug Saf. 2022 Dec;45(12):1551-1552. doi: 10.1007/s40264-022-01240-w. Epub 2022 Oct 12.

A Disproportionality Analysis of Drug-Drug Interactions of Tizanidine and CYP1A2 Inhibitors from the FDA Adverse Event Reporting System (FAERS).

Drug Saf. 2022 Aug;45(8):863-871. doi: 10.1007/s40264-022-01200-4. Epub 2022 Jul 14.

Authors' Response to Yoshihiro Noguchi's Comment on: "A Disproportionality Analysis of Drug-Drug Interactions of Tizanidine and CYP1A2 Inhibitors from the FDA Adverse Event Reporting System (FAERS)".

Drug Saf. 2022 Dec;45(12):1553-1555. doi: 10.1007/s40264-022-01239-3. Epub 2022 Oct 12.

Comment on: "Safety of Marketed Cancer Supportive Care Biosimilars in the U.S.: A Disproportionality Analysis Using the Food and Drug Administration Adverse Event Reporting System (FAERS) Database".

BioDrugs. 2021 May;35(3):373-374. doi: 10.1007/s40259-021-00476-9. Epub 2021 Apr 16.

Novel Adverse Events of Iloperidone: A Disproportionality Analysis in US Food and Drug Administration Adverse Event Reporting System (FAERS) Database.

Curr Drug Saf. 2019;14(1):21-26. doi: 10.2174/1574886313666181026100000.

Letter to the editor concerning the article: 'Potential cerebrovascular accident signal for risankizumab: A disproportionality analysis of the FDA adverse event reporting system (FAERS)'.

Br J Clin Pharmacol. 2023 Aug;89(8):2639-2641. doi: 10.1111/bcp.15746. Epub 2023 Apr 27.

A Disproportionality Analysis of the Adverse Drug Events Associated with Lurasidone in Paediatric Patients Using the US FDA Adverse Event Reporting System (FAERS).

Drug Saf. 2020 Jun;43(6):607-609. doi: 10.1007/s40264-020-00928-1.

Understanding Interindividual Variability in the Drug Interaction of a Highly Extracted CYP1A2 Substrate Tizanidine: Application of a Permeability-Limited Multicompartment Liver Model in a Population Based Physiologically Based Pharmacokinetic Framework.

Drug Metab Dispos. 2022 Jul;50(7):957-967. doi: 10.1124/dmd.121.000818. Epub 2022 May 3.

Author's Reply to Joerg Putzke et al. Comment on: "Safety of Marketed Cancer Supportive Care Biosimilars in the US: A Disproportionality Analysis Using the Food and Drug Administration Adverse Event Reporting System (FAERS) Database".

BioDrugs. 2021 May;35(3):375-377. doi: 10.1007/s40259-021-00474-x. Epub 2021 Apr 16.

Bullous Pemphigoid and Diabetes medications: A disproportionality analysis based on the FDA Adverse Event Reporting System.

Int J Med Sci. 2021 Mar 3;18(9):1946-1952. doi: 10.7150/ijms.55421. eCollection 2021.

引用本文的文献

Authors' Response to Yoshihiro Noguchi's Comment on: "A Disproportionality Analysis of Drug-Drug Interactions of Tizanidine and CYP1A2 Inhibitors from the FDA Adverse Event Reporting System (FAERS)".

Drug Saf. 2022 Dec;45(12):1553-1555. doi: 10.1007/s40264-022-01239-3. Epub 2022 Oct 12.

本文引用的文献

Authors' Response to Yoshihiro Noguchi's Comment on: "A Disproportionality Analysis of Drug-Drug Interactions of Tizanidine and CYP1A2 Inhibitors from the FDA Adverse Event Reporting System (FAERS)".

Drug Saf. 2022 Dec;45(12):1553-1555. doi: 10.1007/s40264-022-01239-3. Epub 2022 Oct 12.

Verification of the "Upward Variation in the Reporting Odds Ratio Scores" to Detect the Signals of Drug-Drug Interactions.

Pharmaceutics. 2021 Sep 22;13(10):1531. doi: 10.3390/pharmaceutics13101531.

Comparison of Signal Detection Algorithms Based on Frequency Statistical Model for Drug-Drug Interaction Using Spontaneous Reporting Systems.

Pharm Res. 2020 Apr 30;37(5):86. doi: 10.1007/s11095-020-02801-3.

Review of Statistical Methodologies for Detecting Drug-Drug Interactions Using Spontaneous Reporting Systems.

Front Pharmacol. 2019 Nov 8;10:1319. doi: 10.3389/fphar.2019.01319. eCollection 2019.

A statistical methodology for drug-drug interaction surveillance.

Stat Med. 2008 Jul 20;27(16):3057-70. doi: 10.1002/sim.3247.

The reporting odds ratio and its advantages over the proportional reporting ratio.

Pharmacoepidemiol Drug Saf. 2004 Aug;13(8):519-23. doi: 10.1002/pds.1001.

Signalling possible drug-drug interactions in a spontaneous reporting system: delay of withdrawal bleeding during concomitant use of oral contraceptives and itraconazole.

Br J Clin Pharmacol. 1999 Jun;47(6):689-93. doi: 10.1046/j.1365-2125.1999.00957.x.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验